Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEXM might be a nice momo trade today.
I don't know if you daytrade, but NEXM might be a nice momo play today. They are having a conference call as I type.
DARA getting to reach some serious milestones . Buy-Buy-BUY
Morning Million. Buy some NEXM and hold on tight.. She's gonna blow up today
Happy Turkey day Cowboy. Hows that new Kitchen coming along?
Time to take a position in DARA bioscience. Do some DD. It's very ready for a run.
Sup? Texas Road House. Fantastic Steak. Good time. Definitely recommended. Shocase Cinima parking lot. East Greenwich.
Looking foward to a big year end climb here. I wouldn't be surprised to hear some talk on CNBC in regards to how there deal with Bayer, has put them in a very profitable position with thier type 2 diabetes oral drug candidate.
Time to load up heavy. by EOY we will be well over $1.00 and not looking back.
Now might be a good time to buy some DARA. I own a few. Very good things happening there. IMO
It is plain to see that this stock is not manipulated. The share count is very low. When she goes, it's gonna be violent, either way. lol
I added a few last week. Our time will come. Buy when no one else wants it.
Awsome thanks for the tip. Putting HEPH on watch.
I'll let u know how the Steak joint is. lol
Oh yeah brother. Our buck is coming. Heading to the Long Horn Steak House tonight with the Softball team. They opened one in the Showcase cinema parking lot.
You play ball?
IMGG bounced right back up today. We missed a nice 20% move. It trades a good dollar vol. these days.
Potential short squeeze coming on CAB. Cabella's Put it on watch.
19% of float short
Happy trading Neighbor
The very same one. 19% of float short and only 15% off it's yr. high.
I am still watching CVM. Also IMGG. It's taken a big tumble off it's highs. Can't quite get a grip on the value of their new scanner. It's an MRI imaging machine, real time 360 degree portable spectacular piece of equipment. But whats it worth?
@ 1.90 it was well over $ 500 mil. mkt. cap.
Weak hands moving on with light vol here today. No worries for me.
I am getting a buck out of this stock.
Have a cabinet and chill. lol
Sup Durk?
we should keep an eye on CAB for a serious short squeeze.
Cabala's
I agree. Shorts and impatient investors will give those that want to accumulate an abundance of cheap shares in the comming weeks. I for 1 will be adding to my position with anything under .20
Happy Holidays
If I had a list of stocks I bought and did not hold on to back in march, it would make you sick.
XRTX bought @ 2.05 sold @ 1.95 it sits @ 11.50
COF in @ 12.79 out @ 13.25 it's @ 37.00
And so on. Picking them is easy, The conviction to hold is where I struggle. I am hoping I have turned a corner. lol
Take a minuite to DD CRBC It's gonna blast off 1 day soon.
DARA BioSciences to Present at the 13th Annual Biotech & Specialty Pharmaceuticals Industry Investor Conference of the New Yo...
Date : 11/17/2009 @ 3:57PM
Source : Business Wire
Stock : DARA BioSciences, Inc. (DARA)
Quote : 0.48 0.0 (0.00%) @ 7:16AM
DARA BioSciences to Present at the 13th Annual Biotech & Specialty Pharmaceuticals Industry Investor Conference of the New Yo...
DARA BioSciences, Inc. (NASDAQ: DARA), a development-stage biopharmaceutical company, today announced that the Company will present at the New York Society of Security Analysts’ 13th Annual Biotech & Specialty Pharmaceuticals Industry investor conference to be held on December 1 in New York City. The New York Society of Security Analysts (NYSSA) serves 11,000 members and 30,000 Wall Street decision makers.
“It is an honour for DARA to be invited to speak,” commented Richard Franco, DARA’s President, CEO and Chairman. ”DARA has two drug candidates in the clinic and this is a great opportunity to update the investment community on their progress.”
DARA is scheduled to present at 1:30pm EST on December 1. Interested parties can access a live web cast of the presentation through the Company’s website at www.darabio.com. A replay of the presentation will be available at the same location.
About DARA BioSciences, Inc.
DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND’s (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. DARA has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.
Check out DSCO. It might be time to buy?
Market gonna shrug off this neg. and continue up. I bought some APP couple days ago. Retail could get real hot. IMO
We got a big bidder here early today.
Yeah, no sellers.
No buyers either though. lol
I am currently in DARA too.
NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
Date : 11/17/2009 @ 8:30AM
Source : Business Wire
Stock : NeoPharm, Inc. (NEOL)
Quote : 0.35 0.0 (0.00%) @ 7:53AM
NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
NeoPharm, Inc. (Other OTC: NEOL.PK) today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA. This multicenter, open label dose escalation trial of LE-DT was performed at Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC and Scottsdale Clinical Research Institute/TGEN, Scottsdale, AZ.
Patients received 50, 65, 85, 110 and 132mg/m2 doses in a cohort of 3 patients per dose until the maximum tolerated dose (MTD) was defined. The MTD was determined to be 110 mg/m2 with growth factor support (9 patients). Neutropenia was the most common toxicity seen in patients receiving higher doses of LE-DT, which is also observed with Taxotere®. Additionally, toxicities experienced by at least three patients included fatigue, alopecia, rash and diarrhea. Most of the non-hematological toxicities observed with LE-DT were grade 1 in nature. Of particular note, in this heavily pretreated cancer patient population, no patient was observed with clinically significant neuropathy, even those patients who received 15 cycles (110mg/m2) and 24 cycles (50mg/m2) of LE-DT. Ten patients experienced some form of infusion-related reaction with LE-DT including chills, rigor, back pain or nausea which was managed by slowing the rate of infusion, except in a few patients who needed antihistamine support. Also, an additional observation was that none of the patients experienced clinically significant edema, which is the common toxicity of Taxotere® when given with Tween 80.
Dr. Aquilur Rahman, President and Chief Executive Officer of NeoPharm commented, “We are very pleased with the absence of serious toxicities with LE-DT therapy for the majority of cancer patients in this trial, particularly peripheral neuropathy and edema, the two treatment limiting toxicities observed with Taxotere®. We are encouraged with the clinical response of LE-DT in this heavily pretreated cancer patient population suffering from various kinds of cancers. A response rate of 45% (partial response and stable disease) is quite noteworthy. We look forward to the clinical outcome of LE-DT in pancreatic and prostate cancer patients in Phase II trials which are being initiated.”
About NeoPharm, Inc.
NeoPharm, Inc., based in Lake Bluff, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer and other drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NeoPharm’s Web site at www.NeoPharm.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," “projects,” "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development programs, the initiation, progress, and outcomes of clinical trials of the Company’s drug product candidates including, but not limited to LE-DT, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to difficulties or delays that may arise in the development, testing, regulatory approval, production, and marketing of the Company's drug and non-drug compounds, including, but not limited to, LE-DT, the Company's possible need to reduce its funding of certain of its development projects in order to conserve its cash resources, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug product candidates, including, but not limited to, LE-DT, that could slow or prevent products coming to market, uncertainty regarding the Company’s ability to commercialize any of its drug product candidates, including, but not limited to, LE-DT, and other risks of the type previously detailed from time to time in filings the Company formerly made with the Securities and Exchange Commission (“SEC”). Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. At the Company’s request, the Company’s obligation to file reports with the SEC was suspended effective February 12, 2009. For the foregoing reasons, you should not rely on these forward-looking statements or our previously filed SEC reports as a prediction of actual future results.
AKRX certainly holding it's ground. Even after their offering.
I am still holding strong here. Patients is key.
Might be time to buy some.
I did
looking good here King. They got an upgrade as well.
Cmon $5.00 baby
I ran out of posts yesterday. It looked like someone had a big order at the ask earlier in the day. This is a good sign
I grabbed a few for a lotto play.
Can't go straight up every day. Vol. way down too. Next leg comming soon. fingers crossed.
That would be a great fight.
Maybe it's time. lol
Shucking and Jiving.
thats funny. I was posting you at the same time. lol
Well, bite my tounge, we got a gapper. lol
I think we could see ACTC make a big move here. If not today, then over the next several weeks. It has a market cap of $50 mil. Fully Dilluted it's much worse than that. But they just got handed $15 mil to continue in the most controversial medicine in existance. Stem cell tech. And they far and away have the brightest mind in Dr. Lanza.
Thats my case. I'm picking up a few
Julio Cezar Chavez in his prime woulda wore him out. lol
Pacquiao is a tough kid.
IMGG looks like it's gonna make another run @ $2.00
Hows your swinging skills?
Julio Cezar Chavez in his prime woulda wore him out. lol
Pacquiao is a tough kid.
Got in @ 2.64. looks like we are gonna have a gapper this morning.
$15 mil. more reasons there is faith the technology in some form will see the light of day. That is a big #